शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
SYNGENENSESyngene International Limited· Healthcare ServicesHighNegative
Announced Thu, 22 Jan, 2026 · 18:36 IST

Syngene Q3 FY26: Revenue down 3%, PAT falls 44% on margin pressure

Revenue declinedEBITDA margin compressionExceptional itemResults View source PDFExplain this filing

SYNGENE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-8.3%Reaction day
₹588.90
prior close
₹563.00
announcement price
After-mkt
timing
Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-1.9%-6.4% vs market
Healthcare Services peers, median of 57sector · industry level-1.8%-6.5% vs sector

On the reaction day the stock moved 6.4 pts less than Nifty Smallcap 250 and 6.5 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+3.4
10m
+4.9
15m
+4.9
30m
+3.5
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-8.3-1.9-6.4-1.8-6.5
Next day
-17.1-1.7-15.4-2.4-14.8
2d
-18.4+0.1-18.5-0.9-17.4
3d
-19.7+0.1-19.8-2.6-17.1
4d
-19.5+0.9-20.4-1.3-18.2
5d
-20.4-0.7-19.7-1.1-19.3
1w
-19.7+3.0-22.6+0.3-20.0
15d
-26.1+2.3-28.4+2.0-28.1
1m
-24.1+2.6-26.7+1.7-25.8
2m
-32.5-8.9-23.7-8.0-24.6
3m
-27.2+6.2-33.4+2.8-29.9
UpDownMarket · Nifty Smallcap 250Sector · Healthcare Services peers, median of 57Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Syngene Q3 FY26 revenue fell 3% YoY to Rs. 917 Cr; 9M revenue up 3% to Rs. 2,702 Cr. EBITDA dropped 26% to Rs. 225 Cr with margin compressing to 24% from 31%. PAT (before exceptional) fell 44% to Rs. 73 Cr. An exceptional charge of Rs. 58 Cr (net of tax) tied to new Labour Code gratuity impact cut PAT after exceptional to Rs. 15 Cr. Management cited ongoing weakness from a single large-molecule client; Bristol Myers Squibb partnership extended to 2035.

Likely market impact

Weak quarter with margin compression and one-off Labour Code charge. BMS extension to 2035 is a long-term positive. Watch for single-client drag to ease.